Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 20/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.58 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624541 | 1.00 | MAP3K5 (0.69) | MAP3K5MAP3K7MAP3K6 | |
| SCHEMBL29624519 | 0.93 | MAP3K5 (0.72) | MAP3K5MAP3K7MAP3K6 | |
| SCHEMBL20523223 | 0.93 | MAP3K5 (0.72) | MAP3K5MAP3K7MAP3K6 | |
| SCHEMBL20522968 | 0.90 | MAP3K5 (0.70) | MAP3K5 | |
| SCHEMBL29624536 | 0.90 | MAP3K5 (0.70) | MAP3K5 | |
| SCHEMBL20523204 | 0.90 | MAP3K5 (0.70) | MAP3K5 | |
| SCHEMBL29624549 | 0.90 | MAP3K5 (0.70) | MAP3K5 | |
| SCHEMBL29624569 | 0.89 | MAP3K5 (0.78) | MAP3K5MAP3K7MAP3K6 | |
| SCHEMBL20522712 | 0.89 | MAP3K5 (0.66) | MAP3K5 | |
| SCHEMBL29624568 | 0.89 | MAP3K5 (0.66) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | PHARMAKEA, INC. | 2020-02-13 | — | — | US | claimed |
| EP-3601250-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | Pharmakea, Inc. (US) | 2020-02-05 | — | — | EP | claimed |
| WO-2018183122-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | SIDECAR THERAPEUTICS, INC. (US) | 2018-10-04 | — | — | WO | claimed |
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | PHARMAKEA, INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3601250-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | Pharmakea, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183122-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | SIDECAR THERAPEUTICS, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | BAX, BAD, BCL2 | MAP3K5 13/4885MAP3K7 16/4885MAP3K6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.